Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 8
2016 18
2017 16
2018 16
2019 18
2020 13
2021 8
2022 8
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. Fendler WP, et al. Among authors: wester hj. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486. doi: 10.1007/s00259-022-06089-w. Epub 2023 Jan 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 36604326 Free PMC article.
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios …
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate …
EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Kratochwil C, et al. Among authors: wester hj. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31440799
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted in several countries in- and outside Europe. PSMA-directed radioligand therapy (PSMA
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, …
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. Weineisen M, et al. Among authors: wester hj. J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18. J Nucl Med. 2015. PMID: 26089548 Free article.
The PSMA affinity of (nat)Ga-/(nat)Lu-PSMA I&T was determined in a competitive binding assay using LNCaP cells. ...RESULTS: PSMA I&T and its cold gallium and lutetium analog revealed nanomolar affinity toward PSMA. ...
The PSMA affinity of (nat)Ga-/(nat)Lu-PSMA I&T was determined in a competitive binding assay using LNCaP cells. ...RESULTS …
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. Baum RP, et al. Among authors: wester hj. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21. J Nucl Med. 2016. PMID: 26795286 Free article.
METHODS: Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA. (68)Ga-PSMA-(N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) ((68)Ga-PSMA) PET/CT was used for patient selection and follow-up …
METHODS: Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA. (68)Ga-PSMA-(N,N'-bis-[2- …
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ, Schottelius M. Wester HJ, et al. Semin Nucl Med. 2019 Jul;49(4):302-312. doi: 10.1053/j.semnuclmed.2019.02.008. Epub 2019 Apr 30. Semin Nucl Med. 2019. PMID: 31227053 Review.
Even though monoclonal antibodies were investigated and introduced as first PSMA-targeted probes, the inherent advantage of fast tumour uptake and rapid excretion of small molecules has shifted the research focus during the last decade to low molecular weight inhibitors wi …
Even though monoclonal antibodies were investigated and introduced as first PSMA-targeted probes, the inherent advantage of fast tumo …
Prostate-Specific Membrane Antigen-Guided Surgery.
Maurer T, Graefen M, van der Poel H, Hamdy F, Briganti A, Eiber M, Wester HJ, van Leeuwen FWB. Maurer T, et al. Among authors: wester hj. J Nucl Med. 2020 Jan;61(1):6-12. doi: 10.2967/jnumed.119.232330. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732677 Free article. Review.
Since its introduction to the diagnostic pathway for prostate cancer management, prostate-specific membrane antigen (PSMA)-ligand PET has demonstrated great potential. PSMA-ligand imaging is increasingly influencing therapeutic decision making, although its impact o …
Since its introduction to the diagnostic pathway for prostate cancer management, prostate-specific membrane antigen (PSMA)-ligand PET …
Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?
Hensbergen AW, van Willigen DM, van Beurden F, van Leeuwen PJ, Buckle T, Schottelius M, Maurer T, Wester HJ, van Leeuwen FWB. Hensbergen AW, et al. Among authors: wester hj. Bioconjug Chem. 2020 Feb 19;31(2):375-395. doi: 10.1021/acs.bioconjchem.9b00758. Epub 2020 Jan 6. Bioconjug Chem. 2020. PMID: 31855410 Free PMC article. Review.
Not only does PSMA provide a target for noninvasive diagnostic imaging, e.g., PSMA-positron emission tomography (PSMA-PET), it can also be used to guide surgical resections of PSMA-positive lesions. The latter characteristic has led to the development …
Not only does PSMA provide a target for noninvasive diagnostic imaging, e.g., PSMA-positron emission tomography (PSMA-P …
Safety and Efficacy of [(177)Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
Tauber R, Knorr K, Retz M, Rauscher I, Grigorascu S, Hansen K, D'Alessandria C, Wester HJ, Gschwend J, Weber W, Eiber M, Langbein T. Tauber R, et al. Among authors: wester hj. J Nucl Med. 2023 Aug;64(8):1244-1251. doi: 10.2967/jnumed.122.265259. Epub 2023 Jun 15. J Nucl Med. 2023. PMID: 37321824
(177)Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new treatment option for metastatic castration-resistant prostate cancer (mCRPC). ...The purpose of this analysis was to evaluate the efficacy and safety of [(177)Lu]-PSMA RLT i …
(177)Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new treatment option for metastatic castrati …
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, Wester HJ, Baum RP. Kulkarni HR, et al. Among authors: wester hj. J Nucl Med. 2016 Oct;57(Suppl 3):97S-104S. doi: 10.2967/jnumed.115.170167. J Nucl Med. 2016. PMID: 27694180 Free article. Review.
A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with (68)Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using …
A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on m …
[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT].
Afshar-Oromieh A, Eiber M, Fendler W, Schmidt M, Rahbar K, Ahmadzadehfar H, Umutlu L, Hadaschik B, Hakenberg OW, Fornara P, Kurth J, Neels O, Wester HJ, Schwaiger M, Kopka K, Haberkorn U, Herrmann K, Krause BJ; Deutsche Gesellschaft für Urologie e. V. (DGU); Deutsche Röntgengesellschaft e. V. (DRG). Afshar-Oromieh A, et al. Among authors: wester hj. Nuklearmedizin. 2023 Feb;62(1):5-19. doi: 10.1055/a-1984-8167. Epub 2023 Feb 6. Nuklearmedizin. 2023. PMID: 36746147 German.
Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. (68)Ga-PSMA-11, (68)Ga-PSMA-I&T, (68)Ga-PSMA-617, (18)F-DCFBC, (18)F-DCFPyL, (18)F-PSMA-1007, (18)F-rhPSMA-7 and (18)F-JK-PSMA-7). ...Besides prostate cancer, …
Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. (68)Ga-PSMA-11, (68)Ga-PSMA-I&T, (68)Ga …
89 results